Φορτώνει......
Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells
BACKGROUND: Redirection of T lymphocytes against tumor antigens can induce dramatic regression of advanced stage malignancy. The use of bispecific antibodies (BsAbs) that bind both the T-cell receptor (TCR) and a target antigen is one promising approach to T-cell redirection. However, BsAbs indiscri...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | J Transl Med |
|---|---|
| Κύριοι συγγραφείς: | , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
BioMed Central
2014
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4272781/ https://ncbi.nlm.nih.gov/pubmed/25496493 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-014-0347-2 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|